Previous Page  536 / 923 Next Page
Information
Show Menu
Previous Page 536 / 923 Next Page
Page Background

60 patients: inter 27%, low 73% Prospective follow up

19Gy HDR single dose

CTCAE v4.0

Median follow up 72 months